"The proposed transaction would combine Novo Nordisk's regulatory, scientific and commercial expertise with Ablynx's strong existing medical teams to optimise the development and global commercialisation of caplacizumab," the Danish company said in a statement. There can be no assurance that any agreement will be reached between the two companies, but Novo Nordisk said that it encourages Ablynx to engage in a negotiated transaction for the benefit of all stakeholders. It said that should any deal be struck, it would keep Ablynx's strong research-and-development base within Ghent, Belgium, and further develop Ablynx as a center of excellence in nanobody discovery and engineering.